Multiomics Insights to Accelerate Drug Development: Will They Hold Their Promises?
- PMID: 37940230
- DOI: 10.1016/j.jacc.2023.09.801
Multiomics Insights to Accelerate Drug Development: Will They Hold Their Promises?
Keywords: drug development; heart failure; ischemic heart disease; multiomics.
Conflict of interest statement
Funding Support and Author Disclosures Dr Tang has served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, WhiteSwell, Kiniksa Pharmaceuticals, Boston Scientific, CardiaTec Biosciences, and Intellia Therapeutics; and has received honorarium from Springer, Belvoir Publishing, and the American Board of Internal Medicine, outside the submitted work. Dr Koenig has received advisory board fees from AstraZeneca, Novartis, Amgen, Pfizer, The Medicines Company, DalCor, Kowa, Corvidia, OMEICOS, Daiichi-Sankyo, Novo Nordisk, New Amsterdam Pharma, TenSixteen Bio, Esperion, and Genentech; has received lecture fees from Bristol Myers Squibb, Novartis, Amgen, Berlin-Chemie, Sanofi, and AstraZeneca; and has received grants and nonfinancial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work.
Comment on
-
Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease.J Am Coll Cardiol. 2023 Nov 14;82(20):1906-1920. doi: 10.1016/j.jacc.2023.09.804. J Am Coll Cardiol. 2023. PMID: 37940228 Free PMC article.
-
Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure.J Am Coll Cardiol. 2023 Nov 14;82(20):1921-1931. doi: 10.1016/j.jacc.2023.08.053. J Am Coll Cardiol. 2023. PMID: 37940229
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources